Differential cannabinoid receptor expression during reactive gliosis: a possible implication for a nonpsychotropic neuroprotection.
Activated microglia and astrocytes produce a large number of inflammatory and neurotoxic substances in various brain pathologies, above all during neurodegenerative disorders. In the search for new neuroprotective compounds, interest has turned to marijuana derivatives, since in several in vitro, in vivo, and clinical studies, they have shown a great ability to control neuroinflammation. Despite the emerging evidence regarding pharmacological activities of cannabinoids, their effective introduction into clinical therapy still remains controversial and strongly limited by their unavoidable psychotropicity. Since the psychotropic effect of cannabinoids is generally linked to the activation of the CB1 receptor on neurons, the aim of our review is to clarify the function of the two cannabinoid receptors on glial cells and the differential role played by them, highlighting the emerging evidence of a CB2-mediated control of neuroinflammation that could liberate cannabinoids from the slavery of their central side effects. Despite the emerging evidence regarding pharmacological activities of cannabinoids, however their effective introduction in the clinical therapy remains still controversial and strongly limited by their unavoidable psychotropicity. Since the psychotropic effect of cannabinoids is generally linked to the activation of CB1 receptor on neurons, aim of our review is to clarify the functioning of the two cannabinoid receptors on glial cells and the differential role played by them, highlighting the emerging evidence of a CB2-mediated control of neuro-inflammation that could liberate cannabinoids from the slavery of the central side effects.
Endocannabinoid Research Group, Department of Experimental Pharmacology, University of Naples Federico II. danieledef@gmail.com
Daniele
D
De Filippis
Antonio
A
Steardo
Alessandra
A
D'Amico
Caterina
C
Scuderi
Mariateresa
M
Cipriano
Giuseppe
G
Esposito
Teresa
T
Iuvone
D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology* / Q000627:therapeutic use; D015870:Gene Expression; D005911:Gliosis / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D017628:Microglia / Q000187:drug effects / Q000502:physiology*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects* / Q000502:physiology; D043885:Receptor, Cannabinoid, CB2 / Q000187:drug effects* / Q000502:physiology
D002186:Cannabinoids; D018696:Neuroprotective Agents; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2